{"groups":[{"description":"Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nErlotinib Hydrochloride: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Treatment (Erlotinib Hydrochloride)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: May 2013 to May 2014"}